Sugi Predict

Sugi Predict / Targets / SERPINA2

SERPINA2

Alpha-1-antitrypsin-related protein · P20848 · SERPINA2 on Sugi Atlas →

2,007 patent compounds predicted against SERPINA2, 1,510 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL10885012 SCHEMBL10885012 0.43 4/20
SCHEMBL796862 SCHEMBL796862 0.53 3/20
SCHEMBL796636 SCHEMBL796636 0.46 3/20
Berzosertib Berzosertib (SCHEMBL3061890) 1.00 1/20
SCHEMBL3050714 SCHEMBL3050714 0.85 1/20
SCHEMBL2485235 SCHEMBL2485235 0.82 1/20
SCHEMBL3052594 SCHEMBL3052594 0.82 1/20
SCHEMBL3051719 SCHEMBL3051719 0.81 1/20
SCHEMBL3057714 SCHEMBL3057714 0.81 1/20
SCHEMBL13137801 SCHEMBL13137801 0.81 1/20
SCHEMBL3064419 SCHEMBL3064419 0.81 1/20
SCHEMBL2527797 SCHEMBL2527797 0.79 1/20
SCHEMBL3052157 SCHEMBL3052157 0.79 1/20
SCHEMBL3056894 SCHEMBL3056894 0.79 1/20
SCHEMBL3042259 SCHEMBL3042259 0.78 1/20
SCHEMBL1288324 SCHEMBL1288324 0.74 1/20
SCHEMBL3058089 SCHEMBL3058089 0.72 1/20
SCHEMBL3058092 SCHEMBL3058092 0.72 1/20
SCHEMBL3061776 SCHEMBL3061776 0.72 1/20
SCHEMBL3699040 SCHEMBL3699040 0.72 1/20

Clinical trials — most relevant to SERPINA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function PHASE4COMPLETED
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography PHASE4UNKNOWN
International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema PHASE2/PHASE3COMPLETED
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency PHASE2/PHASE3COMPLETED
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults PHASE3COMPLETED
Phase III, Efficacy and Safety of Kamada-AAT for Inhalation PHASE3RECRUITING
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency PHASE3COMPLETED
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery PHASE1/PHASE2UNKNOWN
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency PHASE2COMPLETED
Intravenous Alpha-1 Antitrypsin for Hospitalized Patients With COPD Exacerbations (AECOPD Study) PHASE2NOT_YET_RECRUITING
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B) PHASE1/PHASE2COMPLETED
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency PHASE2COMPLETED
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD PHASE2COMPLETED
Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients PHASE2UNKNOWN
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) PHASE2COMPLETED
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency PHASE1/PHASE2COMPLETED
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) EARLY_PHASE1UNKNOWN
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study nanRECRUITING
Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema nanUNKNOWN
Alpha-1 Carrier Genomics Study nanCOMPLETED
Alpha-1 Antitrypsin Deficiency Adult Liver Study nanACTIVE_NOT_RECRUITING
Effect Of Pulmonary Rehabilitation in Patients With Alpha-1 Antitrypsin Deficiency nanCOMPLETED
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease nanACTIVE_NOT_RECRUITING
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals nanCOMPLETED
Belgian Antithrombin Deficiency Registry nanNOT_YET_RECRUITING
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease nanCOMPLETED
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs nanRECRUITING
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD) nanCOMPLETED
Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SERPINA2 binder may also engage these)

ProteinNameSimilarity
P05543 — 0.991 P05543 →
P61640 — 0.991 P61640 →
Q91WP6 — 0.990 Q91WP6 →
Q5R536 — 0.989 Q5R536 →
P61939 — 0.989 P61939 →
Q9GK37 — 0.988 Q9GK37 →
P35577 — 0.988 P35577 →
Q9D7D2 — 0.987 Q9D7D2 →
P26595 — 0.987 P26595 →
P49920 — 0.987 P49920 →
E1BF81 — 0.987 E1BF81 →
P05545 — 0.986 P05545 →
Q9TT35 — 0.986 Q9TT35 →
Q60543 — 0.986 Q60543 →
O54762 — 0.986 O54762 →
Q60396 — 0.986 Q60396 →
A6QPQ2 — 0.986 A6QPQ2 →
Q00898 — 0.985 Q00898 →
Q03734 — 0.985 Q03734 →
Q5R9E3 — 0.985 Q5R9E3 →
P50451 — 0.985 P50451 →
Q8BYY9 — 0.984 Q8BYY9 →
SERPINA6 Corticosteroid-binding globulin 0.984 landscape →
Q86WD7 — 0.984 Q86WD7 →
Q80X76 — 0.983 Q80X76 →
Q6P4P1 — 0.983 Q6P4P1 →
Q5RCR2 — 0.983 Q5RCR2 →
SERPINA3 Alpha-1-antichymotrypsin 0.982 landscape →
Q63556 — 0.982 Q63556 →
P50450 — 0.982 P50450 →